4-Amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies

Journal of Medicinal Chemistry

Volumn 49, Issue 13, 2006, Pages 3916-3925

  Lenzi, Ombretta ^a   Colotta, Vittoria ^a   Catarzi, Daniela ^a   Varano, Flavia ^a   Filacchioni, Guido ^a   Martini, Claudia ^b   Trincavelli, Letizia ^b   Ciampi, Osele ^b   Varani, Katia ^c   Marighetti, Federico ^d   Morizzo, Erika ^d   Moro, Stefano ^d  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIAZOLO[4,3 A]QUINOXALIN 1 ONE DERIVATIVE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR ANTAGONIST; QUINOXALINE DERIVATIVE; THEOPHYLLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CATTLE; CHO CELL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG COMPETITION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IC 50; MOLECULAR MODEL; NEUROMODULATION; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING, COMPETITIVE; CATTLE; CEREBRAL CORTEX; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; HUMANS; LIGANDS; MEMBRANES; MODELS, MOLECULAR; QUINOXALINES; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A3; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 33745667503     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060373w     Document Type: Article

References (42)

1. Jacobson, K. A.; Knutsen, L. J. S. P1 and P2 purine and pyrimidine receptor ligands. In Purinergic and Pyrimidinergic Signalling; Abbracchio, M. P., Williams, M., Eds; Handbook of Experimental Pharmacology, Vol. 151/1; Berlin, Germany, 2001; pp 129-175.
2. Jacobson, K. A.; Gao, Z. G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discovery 2006, 5, 247-264.
3. 3 adenosine receptor with widespread tissue distribution. Mol. Pharmacol. 1993, 44, 524-532.
4. 3 receptor in rat brain. Mol. Pharmacol. 1995, 48, 1038-1045.
5. 2+-ionophore-induced secretion in a rat mast-cell line. J. Pharmacol. Exp. Ther. 1996, 276, 837-845.
6. 3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol. Sci. 1994, 15, 298-306.
7. 3 receptor: sustained cardioprotection. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 6995-6999.
8. Marx, D.; Ezeamuzie, C. I.; Nieber, K.; Szelenyi, I. Therapy of bronchial asthma with adenosine receptor agonists or antagonists. Drug News Perspect. 2001, 14, 89-100.
9. 3 adenosine receptor signaling contributes in airway inflammation and mucus production in adenosine deaminase-deficient mice. J. Immunol. 2004, 173, 1380-1389.
10. 3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin. Cancer Res. 2004, 10, 5895-5901.
11. Merighi, S.; Mirandola, P.; Varani, K.; Gessi, S.; Leung, E.; Baraldi, P. G.; Tabrizi, M. A.; Borea, P. A. A glance at adenosine receptors: a novel target for antitumor therapy. Pharmacol. Ther. 2003, 100, 31-48.
12. 3 adenosine receptor affects cell cycle progression and cell growth. Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 361, 225-234.
13. 3 adenosine receptor antagonists delay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA1 hippocampus in vitro. Br. J. Pharmacol. 2006, 147, 524-532.
14. 2a adenosine binding activities of some 1-aryl-1,4-dihydro-3-methyl[1]benzopyrano[2,3-c-]pyrazol-4-ones, 1-aryl-4,9-dihydro-3-methyl-1H-pyrazolo[3,4-b]quinolin-4-ones, and 1-aryl-1H-imidazo[4,5-b]quinoxalines. J. Med. Chem. 1995, 38, 1330-1336.
15. 1 receptors. Arch. Pharm. (Weinheim, Ger.) 1999, 332, 39-41.
16. Colotta, V.; Catarzi, D.; Varano, F.; Cecchi, L.; Filacchioni, G.; Martini, C.; Trincavelli, L.; Lucacchini, A. Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists. J. Med. Chem. 2000, 43, 3118-3124.
17. Colotta, V.; Catarzi, D.; Varano, F.; Cecchi, L.; Filacchioni, G.; Martini, C.; Trincavelli, L.; Lucacchini, A. 1,2,4-Triazolo[4,3-a]-quinoxalin-1- one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists. J. Med. Chem. 2000, 43, 1158-1164.
18. Colotta, V.; Catarzi, D.; Varano, F.; Filacchioni, G.; Martini, C.; Trincavelli, L.; Lucacchini, A. Synthesis and structure-activity relationships of a new set of 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as adenosine receptor antagonists. Bioorg. Med. Chem. 2003, 11, 3541-3550.
19. 2A adenosine receptor antagonists. Bioorg. Med. Chem. 2003, 11, 5509-5518.
20. 3 adenosine receptor antagonists. Arch. Pharm. (Weinheim, Ger.) 2004, 337, 35-41.
21. 3 adenosine receptor antagonists: synthesis, pharmacological and ligand-receptor modeling studies. J. Med. Chem. 2004, 47, 3580-3590.
22. 3 adenosine receptor antagonists. Bioorg. Med. Chem. 2005, 13, 705-715.
23. 3 adenosine receptor antagonists: synthesis, biological evaluation and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives. J. Med. Chem. 2005, 48, 7932-7945.
24. 3 adenosine receptors. Biochem. Pharmacol. 2003, 65, 1675-1684.
25. Klotz, K.-N.; Messung, J.; Hegler, J.; Owman, C.; Kull, B.; Fredholm, B. B.; Lohes, M. J. Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn-Schiedeberg's Arch. Pharmacol. 1998, 357, 1-9.
26. Moro, S.; Gao, Z. G.; Jacobson, K. A.; Spalluto, G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Med. Res. Rev. 2006, 26, 131-159.
27. Moro, S.; Deflorian, F.; Spalluto, G.; Pastorin, G.; Cacciari, B.; et al. Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling. Chem. Commun. (Cambridge) 2003, 24, 2949-2956.
28. 3 adenosine receptor as an example. Trends Pharmacol. Sci. 2005, 26, 44-51.
29. 3 adenosine receptor antagonists: Pyrazolo[4, 3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study. J. Med. Chem. 2005, 48, 152-162.
30. 3 receptor antagonists: an update. Curr. Med. Chem. 2006, 13, 639-645.
31. Moro, S.; Bacilieri, M.; Deflorian, F.; Spalluto, G. G protein-coupled receptors as challenging druggable targets: insights from in silica studies. New J. Chem. 2006, 30, 301-308.
32. 3 adenosine receptor. J. Biol. Chem. 2002, 277, 19056-19063.
33. 2A adenosine binding activity of some pyrano[2,3-c]pyrazol-4-ones. Farmaco 1998, 53, 189-196.
34. 3 adenosine receptors. Mol. Pharmacol. 2000, 57, 968-975.
35. i and the concentration of inhibitor which causes fifty percent inhibition (ICso) of an enzyme reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
36. OpenMosix: http://www.openMosix.org, 2004.
37. MOE (The Molecular Operating Environment), version 2005.06; Chemical Computing Group Inc. (1010 Sherbrooke Street West, Suite 910, Montreal, Canada H3A 2R7); http://www.chemcomp.com.
38. Stewart, J. J. P. MOPAC 7: Fujitsu Limited: Tokyo, Japan, 1993.
39. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289, 739-745.
40. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5196.
41. Baxter, C. A.; Murray, C. W.; Clark, D. E.; Westhead, D. R.; Eldridge, M. D. Flexible Docking Using Tabù Search and an Empirical Estimate of Binding Affinity. Proteins: Struct., Funct., Genet. 1998, 33, 367-382.
42. Halgren, T. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput. Chem. 1996, 17, 490-519.